35 results on '"Feely, Meghan A."'
Search Results
2. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
3. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
4. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
5. Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
6. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
7. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
8. 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
9. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
10. Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
11. Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program
12. Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective
13. P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis
14. Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
15. Photosensitivity and Photoreactions in Pediatric Skin of Color
16. Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review
17. Baricitinib 2 mg for the treatment of atopic dermatitis in North America : Long‐term efficacy and patient‐reported outcomes
18. 33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada
19. 33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study
20. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry.
21. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
22. 43054 The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naïve and -experienced patients: A post-hoc analysis of patients receiving treatment according to US labels
23. 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
24. 43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program
25. 43113 Ixekizumab improves fatigue, an important patient-reported outcome in psoriasis
26. Solid facial edema – chronic head and neck lymphedema: The Mayo Clinic Experience: 1429
27. LASER TREATMENT OF SURGICAL AND TRAUMATIC SCARS: #158
28. Two Cases of Lichen Striatus with Prolonged Active Phase
29. Cutaneous lymphatics and chronic lymphedema of the head and neck
30. Inappropriate Application of Nodule Management Guidelines in Radiologist Reports Before and After Revision of Exclusion Criteria
31. Cutaneous lymphatics and chronic lymphedema of the head and neck.
32. Novel psoriasis therapies and patient outcomes, Part 3: Systemic medications.
33. Novel psoriasis therapies and patient outcomes, part 2: biologic treatments.
34. Novel psoriasis therapies and patient outcomes, part 1: topical medications.
35. Inappropriate application of nodule management guidelines in radiologist reports before and after revision of exclusion criteria.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.